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Abstract
Background: The diagnosis and treatment of malaria is often based on syndromic presentation
(presumptive treatment) and microscopic examination of blood films. Treatment based on
syndromic approach has been found to be costly, and contributes to the development of drug
resistance, while microscopic diagnosis of malaria is time-consuming and labour-intensive. Also,
there is lack of trained microscopists and reliable equipment especially in rural areas of Nigeria.
However, although rapid diagnostic tests (RDTs) have improved the ease of appropriate diagnosis
of malaria diagnosis, the cost-effectiveness of RDTs in case management of malaria has not been
evaluated in Nigeria. The study hence compares the cost-effectiveness of RDT versus syndromic
diagnosis and microscopy.
Methods: A total of 638 patients with fever, clinically diagnosed as malaria (presumptive malaria)
by health workers, were selected for examination with both RDT and microscopy. Patients positive
on RDT received artemisinin-based combination therapy (ACT) and febrile patients negative on
RDT received an antibiotic treatment. Using a decision tree model for a hypothetical cohort of
100,000 patients, the diagnostic alternatives considered were presumptive treatment (base
strategy), RDT and microscopy. Costs were based on a consumer and provider perspective while
the outcome measure was deaths averted. Information on costs and malaria epidemiology were
locally generated, and along with available data on effectiveness of diagnostic tests, adherence level
to drugs for treatment, and drug efficacy levels, cost-effectiveness estimates were computed using
TreeAge programme. Results were reported based on costs and effects per strategy, and
incremental cost-effectiveness ratios.
Results: The cost-effectiveness analysis at 43.1% prevalence level showed an incremental cost
effectiveness ratio (ICER) of 221 per deaths averted between RDT and presumptive treatment,
while microscopy is dominated at that level. There was also a lesser cost of RDT ($0.34 million)
compared to presumptive treatment ($0.37 million) and microscopy ($0.39 million), with
effectiveness values of 99,862, 99,735 and 99,851 for RDT, presumptive treatment and microscopy,
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respectively. Cost-effectiveness was affected by malaria prevalence level, ACT adherence level,
cost of ACT, proportion of non-malaria febrile illness cases that were bacterial, and microscopy
and RDT sensitivity.
Conclusion: RDT is cost-effective when compared to other diagnostic strategies for malaria
treatment at malaria prevalence of 43.1% and, therefore, a very good strategy for diagnosis of
malaria in Nigeria. There is opportunity for cost savings if rapid diagnostic tests are introduced in
health facilities in Nigeria for case management of malaria.
Background
Malaria is the number one cause of mortality and morbid-
ity in Nigeria and accounts for 25 and 30% of infant and
childhood deaths, respectively and 11% maternal mortal-
ity [1]. Most victims of malaria still die because the disease
is not diagnosed in time by health workers [2]. The diag-
nosis of malaria has traditionally relied on the clinical
presentation of malaria symptoms [3,4] and microscopi-
cal examination of Giemsa-stained blood films. Diagnosis
based on symptoms alone is unreliable because the symp-
toms of malaria are non-specific, overlapping with other
febrile diseases [5]. Studies in Africa have shown that
more than 50% of patients clinically diagnosed with
malaria have illnesses attributable to some other causes
[6-8]. This results in over-diagnosis of malaria [9], over-
prescription of anti-malarial drugs, under-diagnosis and
inappropriate treatment of non-malarial febrile illnesses
(NMFI) [10-14]. It is also costly and associated with side-
effects [6] and ultimately contributes to the development
and spread of drug resistance [7,15,16].
Although microscopy is considered to be the gold stand-
ard for malaria diagnosis [16,17], in many malaria-
endemic areas like Nigeria, there is lack of trained micro-
scopists and reliable equipment [18].
As anti-malarial drug costs increase, diagnostic methods
are becoming a crucial component of malaria control and
prevention. Treating all fevers with anti-malarial medica-
tions will no longer hold with the introduction of a
higher-priced artemisinin-based combination therapy
(ACT), which was introduced in Nigeria in 2005 as the
first-line anti-malarial drug, as a result of extensive resist-
ance to chloroquine and sulphadoxine-pyrimethamine
(SP) [19]. It has been noted that the cost of ACT is up to
ten times more than chloroquine [20]. Although the
prices of ACT have reduced recently, the recommended
ACT (artemether-lumefantrine) in Nigeria is still sold at
$6 to $8. Thus with the high cost of treatment for malaria,
there is an increased need to ensure that malaria is cor-
rectly diagnosed prior to treatment [21].
Developments in rapid diagnostic tests (RDTs) based on
the demonstration of parasite antigens have opened new
possibilities for improved remote malaria diagnosis that is
independent of microscopic diagnosis [18,22-25]. Several
commercially available tests are sensitive, specific, and
stable under operational conditions [14,26,27]. WHO
recommended that parasite-based diagnosis should be
used in all cases of suspected malaria with the possible
exception of children in high-prevalence areas and in cer-
tain other situations [28]. RDTs can be performed close to
home in settings with no sophisticated infrastructure, and
they do not require much skill although some level of
training is needed in order for RDTs to be used properly.
In spite of these advances, there is paucity of cost-effective-
ness data of RDTs in highly malaria endemic countries
like Nigeria. Although studies have investigated the cost-
effectiveness of RDT in Africa [14,28-30], little is known
on its cost-effectiveness in Nigeria. This paper reports an
economic evaluation carried out to determine whether the
use of RDT for diagnosis of malaria is cost-effective, when
compared with clinical diagnosis and microscopy-based
diagnosis of malaria. The cost-effectiveness analysis is
based on the model by Shillcutt et al [28], with data on
cost and malaria epidemiology obtained from south-east
Nigeria. The information generated by this study will help
design policy measures to strengthen the diagnosis and
treatment components of the national malaria control
strategy especially in the light of the introduction of ACT
in Nigeria.
Methods
Study area
The study was undertaken in urban and rural districts of
Enugu East Local Government Area in Enugu State, south-
east Nigeria, with a 2006 population of 279,089 [31]. It
has 12 public health centres and 30 private clinics and
hospitals. The health centres are stratified into three
groups of high, medium and low level of infrastructures
based on the number of staff, availability of relevant facil-
ities, such as maternity beds and utilization rates. All the
centres have drug dispensing units, but no laboratory
facilities. There is all year high transmission rate of
malaria in the study area. Patients were prospectively
recruited over a 24-month period (between 2005 to 2007)
in order to account for seasonal variations in malaria
occurrence.Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
Page 3 of 15
(page number not for citation purposes)
Overall study design and model used for CEA
A decision tree model (Figure 1) was used for cost-effec-
tiveness analysis using a hypothetical cohort of 100,000
patients. The patients entered the model at the point at
which a decision is made between use of symptoms only,
a rapid diagnostic test or microscopy for diagnosis of
malaria in a patient presenting to a health worker with
symptoms suggestive of malaria. Real-life data on cost and
malaria epidemiology were locally obtained from out-
patients attending health clinics. The estimation of effec-
tiveness was done based on the model by Shillcutt et al
[28] and along with the cost and epidemiology data, avail-
able evidence on effectiveness was used to populate the
model. Figure 1 illustrates the decision tree that starts with
patients who come to the health facility with malaria
symptoms. This proceeds through diagnosis and treat-
ment to disease outcomes depending on the sensitivity
and specificity of each diagnostic strategy. Presumptive
diagnosis and treatment of patients served as the base
intervention.
Sampling and sample size
Four out of the six districts with at least one highly or
medium developed health centre each (two rural and two
urban) were purposively chosen. In each of the chosen
district, one health centre was chosen as a base clinic for
the study. All patients presenting at the centres with his-
tory of fever or non-specific symptoms or signs suggestive
of malaria (e.g. headache only, chills, rigors) and diag-
nosed clinically as having malaria by the health facility
personnel were recruited for the study. However, those
who have taken anti-malarial drugs, and those refusing to
participate were excluded from the study.
The required number of blood smear positive patients was
calculated according to the following parameters:
expected sensitivity of microscopic test = 90%, precision =
5% and alpha error = 0.05. This gave a sample size of 136.
This was doubled taking into account a stratified analysis
by age group category (0-4 years and 5 years and above).
Similar parameters (with expected specificity of 90%)
were used to calculate the required number of blood
smear negative patients. The minimum final sample size
was, therefore, fixed at 300 positive and 300 negative sub-
jects, giving a total of 600 individuals.
Data collection
Patients presenting to the facility were seen by health
workers at the facility and those who had symptoms sug-
gestive of malaria had their axillary temperature taken and
recorded after which the health worker took a decision as
to whether the patient had malaria or not. Those consid-
ered to have malaria were recruited for the study. Follow-
ing an informed consent, information was then obtained
from such patients using pre-tested interviewer-adminis-
tered questionnaire on patient's socio-economic and
demographic background, the presenting symptoms, his-
tory of treatment, malaria specific knowledge and house-
hold practices to diagnose and treat malaria. Patients
clinically diagnosed as having malaria had capillary blood
samples taken by a single finger puncture by the health
workers for both microscopy and RDTs.
Root decision tree Figure 1
Root decision tree.Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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Two thick and one thin blood films (as a single slide can-
not exclude infection) was prepared from each sample.
The microscopical examination of the standard Giemsa-
stained blood films was prepared in the field and read by
a microscopist. The smears were examined with 100×
magnification under oil-immersion objectives.
At the same time, RDTs were conducted using ICT Malaria
Combo Cassette Test (ML02)(ICT Diagnostics, Cape
Town, South Africa) and read according to the manufac-
turers' instructions by the facility health workers who were
trained over a three-day period by the study coordinators.
The sensitivity and specificity of the test in another setting
is put at 96% and 95%, respectively [26].
Following diagnosis, patients with a positive result
received an artemisinin-based combination therapy
(ACT)(dihydroxy-artemisinin/piperaquine). Parasitaemia
demonstrated by microscopic tests was used as the "gold
standard" to compare symptom-based, microscopy-based
and RDT-based diagnosis. All patients who were RDT and
microscopy negative were given amoxicillin and referred
to a secondary facility for further investigation and man-
agement.
Household visits to the patients took place twice weekly
for three weeks for a post-diagnosis survey. On the first
week, the blister pack at the patient's home was examined
for any remaining tablets to assess adherence to ACT. Ver-
bal confirmation of completion of all doses with the pres-
ence of an empty blister pack and correct description of
how the dose was taken was regarded as complete adher-
ence. On day 21, the clinical outcome of the illness was
noted. This was assessed as the presence or otherwise of
occurrence of fever and other initial symptoms at any time
within the 21-day period following completion of treat-
ment. The post-diagnosis survey included further ques-
tions regarding cost of any initial or follow-up treatment,
and household assets. Expenditure on drugs and other
items was recorded with the aid of pictorial diagrams.
Data analysis
The three alternatives pathways considered in this analysis
for diagnosis and treatment or malaria are symptomatic
treatment, treatment following diagnosis with RDT, and
treatment following microscopic diagnosis.
Cost data
Cost data used was based on the consumer and provider
perspectives (Table 1). Consumer costs included cost of
registration, drug, laboratory, admission and transporta-
tion to health facility. Provider costs were those of capital
and recurrent items for malaria diagnosis and treatment.
These included cost of staff time, training and supervision,
unit cost of RDT test kit, cost of consumables, such as lan-
cet, cotton wool, methylated spirit, reagents for micros-
copy, slides, hand gloves, ACT, amoxicillin, and oral and
intravenous quinine. Out-patient costs per visit, in-patient
costs per day, costs of transportation, insurance and wast-
ages were also included. Costs of using health centres and
hospitals were also differentiated.
Outcome and effectiveness
Health outcome was measured in terms of deaths averted
based on the use of the alternative diagnostic strategies. In
other to estimate such an outcome for the diagnostic and
treatment options, sensitivity of RDT and microscopy,
estimates of adherence, efficacy of the drugs used, and
risks of disease progression as well as recovery have been
used based on the model by Shillcutt et al [28]. The vari-
ous estimates used to determine outcome are shown in
Table 2. This led to the determination of the number of
deaths that would be averted by employing the different
diagnostic methods.
Cost-effectiveness analysis
The model for cost effectiveness analysis that was used
was based on that developed by Shillcutt et al [28]. Tree-
Age software was used to run the model for the hypothet-
ical cohort of 100,000. Based on the values of costs and
outcomes determined, cost effectiveness estimates were
determined for the alternative strategies. In addition, an
incremental cost effectiveness ratio (ICER) was deter-
mined for RDT and microscopy with presumptive diagno-
sis as the base strategy. ICER was computed for RDT and
microscopy as the ratio of the difference between their
costs and outcomes relative to those of presumptive diag-
nosis. All costs are presented in US dollars.
Sensitivity analysis
The parameters considered for sensitivity analysis were
malaria prevalence level, proportion of non-malaria
febrile illness that are bacterial, sensitivity of RDT and
microscopy, and adherence levels to ACT, and cost of
RDT, ACT and amoxicillin.
The prevalence level of 43.1% considered indicates the
proportion of those clinically diagnosed for treatment
who had malaria based on the gold standard test (micro-
scopy). Sensitivity of the diagnostic tests was considered
as the extent to which the test correctly identified those
who had the disease, and specificity as the extent to which
it identified those who did not have the disease.
Results
Characteristics of study respondents
As shown in Table 3, of the 638 patients recruited for this
study, 317 (49.7%) and 321 (50.3%) were from the urban
and rural areas, respectively. The majority of the respond-
ents 423 (66.3%) were above 30 years and more than aMalaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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Table 1: Model Parameter Values
No. Disease Parameter Estimate Source
P1 Malaria prevalence 43.1% Uzochukwu 2008 [42]
P2 Febrile outpatients aged ≥ 5 years
P3 Proportion of NMFI cases that were bacterial 10% Shillcutt et al. 2008
P4 Probability that a NMFI received an antibiotic 100% Uzochukwu 2008
P5 RDT sensitivity 90% Uzochukwu 2008, Beadle et. al, 1994, Craig et al., 2002, 
Bell et. al. 2005
P6 Presumptive treatment sensitivity 100% Uzochukwu. 2008
P7 Microscopy sensitivity 82% Uzochukwu. 2008, Shillcutt et. al. 2008, Reyburn et al., 
2004
P8 RDT specificity 91% Uzochukwu. 2008, Mueller et al., 2007 Bell et al. 2005, 
WHO, 2000
P9 Presumptive treatment specificity 0% Uzochukwu. 2008
P10 Microscopy specificity 87% Uzochukwu. 2008
P11 Probability of adherence -- ACT 80% Uzochukwu. 2008, Depoortere et al., 2004, Fogg et al., 
2004
P12 Probability of adherence amoxicillin 80% Assumption
P13 ACT efficacy (for malaria) 95% Uzochukwu. 2008. Shillcutt et. al., 2008, Lefevre et. al., 
2001
No Disease Parameter Estimate Source
P14 Amoxicillin efficacy (for malaria) 0% Assumption
P15 ACT efficacy (for bacterial infection) 0% Assumption
P16 Amoxicillin efficacy (for bacterial infection) 75% Shillcutt et. al. 2008
P17 ACT efficacy (for viral infection) 0% Assumption
P18 Amoxicillin efficacy (for viral infection) 0% Assumption
Treatment seeking behaviour
P19 Outpatient visit at a health centre 1-P20 Shillcutt et.al., 2008
P20 Outpatient visit took place in a hospital 32% Shillcutt et.al., 2008
P21 Patient with severe illness went to hospital for inpatient care after 
treatment failure
48% Shillcutt et. al., 2008, McCombie, 1996
P22 Patient with uncomplicated illness returned to clinic for outpatient 
care after treatment failure
48% Shillcutt et.al., 2008
P23 Malaria not effectively treated led to severe disease (age ≥ 5) 1% Shillcutt et. al. 2008Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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third of the ill persons, 244 (38.2%), were below five
years of age. A majority of the ill persons, 439 (68.8%),
are females. Most of the respondents (81.7%) had one
form of education or another. Their occupational status
shows that petty traders are 139(21.8%), farmers
129(20.2), civil servants 97(15.2), self-employed
101(15.8%) and 91 (14.3%) are unemployed.
Microscopy and RDT tests results
Out of 638 patients recruited, 275 (43.1%) had micro-
scopic examination of blood smear positive for malaria
parasites, 238 (37.3%) were positive for RDT, 224
(35.1%) were positive for both microscopy and RDT, 13
(2.04%) were positive for RDT but negative for micros-
copy, 49 (7.7%) were positive for microscopy but negative
for RDT and 352 (55,2%) were negative for both micros-
copy and RDT. The mean total patient cost (Drugs, con-
sultation, registration) was $2.52 (SD = $3.63), RDT cost
was $0.76 and microscopy $1.30.
Base case result at malaria prevalence level of 43.1%
The cost-effectiveness analysis at this prevalence level
showed an incremental cost effectiveness ratio (ICER) of
$221 per death averted between RDT and syndromic treat-
ment while microscopy is dominated at that level (Table
4). For the patient cohort of 100,000, there is also a lesser
cost of RDT ($0.34 million) compared to presumptive
treatment ($0.37 million) and microscopy ($0.39 mil-
lion) with effectiveness values of 99,862, 99,735 and
99,851 deaths averted for RDT, presumptive treatment
and microscopy respectively.
Sensitivity analysis
Different prevalence level from 20% to 60%
ICER was sensitive to deterministic values of malaria prev-
alence. Table 5 shows that for all levels of prevalence that
are less than 40%, RDT was more cost effective than
microscopy and syndromic approach. Further analysis
also showed that at prevalence rate of 20% and 30%, RDT
still has most attractive values both in cost and effect
while microscopy is dominated at all levels.
Proportion of non-malaria febrile illness cases that werebacterial
Table 6 shows that RDT is more cost saving than the other
diagnostic strategies even when the sensitivity is measured
at different levels between 5% to 15%. Cost values for
RDT increases with reduction in the proportion of NMFI
and microscopy is dominated at all levels considered.
P24 Malaria not effectively treated led to severe disease (age <5) 7.50% Shillcutt et. al. 2008
P25 Bacterial illness not effectively treated led to severe disease (age ≥ 5) 15% Shillcutt et. al. 2008
P26 Bacterial illness not effectively treated led to severe disease (age<5) 30% Shillcutt et. al. 2008
P27 Viral illness not effectively treated led to severe disease (age ≥ 5) 0% Assumption
P28 Viral illness not effectively treated led to severe disease (age<5) 0% Assumption
P29 Severe malaria led to neurological sequelae (age ≥ 5) 1.50% Shillcutt et. al. 2008
P30 Severe malaria led to neurological sequelae (age<5) 3.50% Shillcutt et. al. 2008
P31 Severe bacterial infection led to neurological sequelae (age ≥ 5) 3.80% Shillcutt et. al. 2008
P32 Severe bacterial infection led to neurological sequelae (age<5) 2% Shillcutt et. al. 2008
P33 Inpatient with severe malaria attending an inpatient facility died 
(all ages)
10% Shillcutt et. al. 2008
P34 Inpatient with severe bacterial illness attending an inpatient facility 
died (all ages)
15% Shillcutt et. al. 2008
P35 Patient with severe malaria that did not return for formal care would 
die (all ages)
25% Shillcutt et. al. 2008
P36 Patient with severe bacterial illness that did not return for formal care 
would die (all ages)
P35 Assumption
Table 1: Model Parameter Values (Continued)Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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RDT and microscopy sensitivity
ICER was found to sensitive to changes in RDT sensitivity
(Table 7), but robust to changes in microscopy sensitivity
(Table 8). RDT is cost-saving at the base level of 90% RDT
sensitivity with costs increasing with rise in RDT sensitiv-
ity. Reduction in sensitivity of microscopy also led to a
reduction in costs of microscopic diagnosis strategy. How-
ever, microscopy is dominated at all deterministic values
of RDT and microscopy considered.
Adherence to ACT
As shown in Table 9, better adherence is associated with
cost reduction for all diagnostic approaches with a corre-
sponding decrease in the ICER. However, microscopy is
also dominated at all the deterministic values used.
Costs of the individual diagnostic strategies
ICER was sensitive to changes in cost of RDT. With dou-
bling of cost of RDT from $0.76 to $1.14, use of RDT
option becomes less cost-effective than presumptive treat-
ment at a malaria prevalence level of 40% (Table 10).
Considering various prevalence levels, RDT was found to
be less cost-effective at all prevalence levels above 30%.
Despite doubling of costs of RDT, microscopy is found to
be more costly at all malaria prevalence levels though not
so when compared with presumptive treatment strategy.
Cost of ACT
ICER was very sensitive to a 50% rise in cost of ACT (Table
11). RDT remains more cost-effective than the other diag-
nostic options at a prevalence level of 40% though with
an ICER value of 51,008 which is relatively very high. At
malaria prevalence level of above 40%, RDT is more cost-
effective than microscopic and presumptive diagnosis,
and at levels below 40%, it still dominates both strategies.
With a reduction in cost of ACT by half from $2.50 to
$1.25, presumptive treatment will be more cost-effective
than RDT and microscopy at malaria prevalence level of
40%. At lower prevalence rates of 20% and 30%, micros-
copy is dominated relative to presumptive treatment with
ICER values of 313 and 411 respectively.
Table 2: Cost estimates used in model
Diagnostics Estimate Source
C1 PT
C2 RDT $0.76 Uzochukwu. 2008
C3 Microscopy $1.30 Uzochukwu. 2008
Drugs Uzochukwu. 2008
C4 ACT adult dose $2.50 Uzochukwu. 2008
C5 Amoxicillin $0.74 Shillcutt et al. 2008
C6 Oral quinine (10 mg/kg every 8 hours for 7 days 3.12 Shillcutt et al., 2008
C7 Intravenous quinine (initial dose-20 mg/kg over 4 hours $0.55 Primary data- University of Nigeria Teaching Hospital
C8 Intravenous quinine (per day after -- 10 mg/kg every 8 hours $0.82 Primary data- University of Nigeria Teaching Hospital
C9 Drugs for severe bacterial infection 2*C5 Assumption
Cost Weight
C10 Children cost as % of cost of adult dose 1.25 Shillcutt et al., 2008
C11 Drug/RDT wastage, transport, insurance Assumption
C12 RDT training, additional staff time & QC as % of cost $0.076 Primary data- University of Nigeria Teaching Hospital
Outpatient
C13 Patient costs outpatient $0.69 Uzochukwu 2008
C14 Outpatient cost that are fixed (26%) $0.18 Shillcutt et. al. (2008)
C15 Outpatient costs that are drugs (37%) $0.26 Shillcutt et. al. (2008)
C16 Health centre facilities (per visit) $0.8 Uzochukwu 2008
C17 Hospital facilities (per visit) $3.90 Uzochukwu 2008
Inpatient
C18 Patient cost for attending inpatient facility 
(including transport but excluding fees and cost of patient and 
caretaker time)
$3.00 Uzochukwu 2008
C19 Proportion of inpatient costs that were drugs 17% Uzochukwu 2008
C20 Proportion of inpatient facility costs that were fixed
C21 Provider cost: cost of inpatient faciliy per day $14.15 Nelson et al. 1995, Kirigia et al., 1998, Barnum & Kutzin, 1993
C22 Average length of stay in days as an inpatient when died 
(all illnesses)
2 days Primary data- University of Nigeria Teaching Hospital
C23 Average length of stay in days as an inpatient when had severe 
malaria and recovered.
4.5 days Primary data- University of Nigeria Teaching Hospital
C24 Average length of stay as an inpatient when had severe 
bacterial infection and recovered
7.5 days Primary data- University of Nigeria Teaching HospitalMalaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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Cost of antibiotics (amoxicillin)
As shown in Table 12, a reduction in the price of amoxi-
cillin by 50% gave RDT more preferred values than the
other diagnostic strategies for prevalence levels up to 60%.
At the prevailing prevalence of 40%, RDT is less costly and
microscopy is dominated, and at lower prevalence levels,
microscopy is dominated by extended dominance. Unlike
when there was decrease in the cost of amoxicillin, ICER
was robust to a corresponding percentage increase in the
cost of amoxicillin (Table 13). Microscopy was dominated
at malaria prevalence levels of 40% or less, while pre-
sumptive treatment was found more cost-effective than
other strategies at higher prevalence levels.
Discussion
The study demonstrates the cost-effectiveness of RDTs
over microscopy and syndromic approach. The results are
consistent with results from a previous study [28], which
showed that RDTs are cost-effective relative to syndromic
approach and microscopy. Also the results of the present
study are similar with a study in lower level health facili-
ties in Zambia, which was conducted within the actual
malaria context using field-based data in a malarious pop-
ulation [30]. Surprisingly, microscopy malaria diagnosis
was less effective than expected which goes to challenge
the fact that microscopy is the gold standard for malaria
diagnosis [32].
More than 50% of patients who were diagnosed as having
malaria through the syndromic approach, and who may
have received anti-malarials, turned out to be parasite-
negative. Thus this study demonstrated that over-diagno-
sis and, therefore, over-prescription of anti-malarials, may
be reduced through the use of RDTs among this popula-
tion at health centres. Malaria over-diagnosis is still a
major public health problem in Africa with studies sug-
gesting between 50% and 99% of those prescribed anti-
malarials being test-negative, depending on endemicity in
the clinical setting [8,33-35]. The ability to rule out
malaria can also lead to more opportune diagnosis and
treatment of other causes of fever, such as acute respira-
tory infection, typhoid fever and meningitis and avoid-
Table 3: Socio-demographic characteristics of respondents and 
ill persons
Variables Number (%)
Residence
Urban 317 (49.7)
Rural 321 (50.3)
Age of Respondents (years)
Below 30 215 (33.7)
30 and above 423 (66.3)
Age of sick person (years)
Under 5 244 (38.2)
5 -- 15 233 (36.6)
Above 15 161 (25.2)
Sex of Respondents
Female 567 (88.9)
Male 72 (11.1)
Sex of ill person
Female 439 (68.8)
Male 199 (31.2)
Marital status
Ever married 538 (84.3)
Single 100 (15.7)
Educational status
No education 117 (18.3)
Primary 207 (32.5)
Secondary 285 (44.7)
University 29 (4.5)
Occupational status
Farmer 129 (20.2)
Unemployed 91 (14.3)
Civil servant 97 (15.2)
Petty trading 139 (21.8)
Self employed 101 (15.8)
Big business man/woman 19 (3.0)
Private employment 4 (0.6)
Others 30 (4.7)
Table 4: Base Case Result at Malaria Prevalence level of 40%
Baseline Cohort of 100,000 Malaria Cases from the TreeAge Result
Strategy Cost($) Incremental cost ($) Effect Incremental effect Death Averted Incremental cost per death 
averted ($)
Presumptive treatment 365,426 99,735
RDT 337,466 -27,960 99,862 127 4 -221
Microscopy 394,247 28,821 99,851 116 4 257Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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ance of the exposure of those without malaria to any side-
effects of the drug and the restriction of anti-malarials to
true test-positives.
Health workers might have altered their normal practice
as a result of the study (Hawthorne effect), thus obeying
test results and prescribing ACT only to those who are
RDT positive. In real practice (absence of the research
team), this may not be so, as studies have shown that anti-
malarials are prescribed by health workers even if test
results are negative [9,13]. Undoubtedly, this will affect
the cost-effectiveness of RDTs. Therefore, it is important
that policy makers make effort to encourage health work-
ers to use the test results as a guide for treatment decisions.
The sensitivity analysis at various levels of prevalence
stresses the relevance of RDT under a low prevalence level.
However, as has been noted the better health outcome
with RDT compared to presumptive treatment does not
mean improved treatment of true malaria cases, since sen-
sitivity of presumptive treatment is higher than that of
RDT [28]. Instead, it demonstrates improvement on treat-
Table 5: Sensitivity Report by Different Prevalence Level from 20% to 60%
P1 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.2 RDT $329,823 99,836 $3
M $388,888 99,826 $4 (Ext Dom)
PT $390,737 $60,914 99,662 174 $4 $350
0.3 RDT $333,644 99,849 $3
PT $378,081 $44,437 99,699 150 $4 $296
M $391,568 99,839 $4 (Dominated)
0.4 RDT $337,466 99,862 $3
PT $365,426 $27,959 99,735 127 $4 $221
M $394,247 99,851 $4 (Dominated)
0.5 RDT $341,288 99,875 $3
PT $352,770 $11,482 99,772 103 $4 $111
M $396,926 99,864 $4 (Dominated)
0.6 PT $340,114 99,808 $3
RDT $345,110 99,888 $3 (Dominated)
M $399,605 99,877 $4 (Dominated)
Table 6: Sensitivity Report by Proportion of NMFI cases that were bacterial
P3 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.05 RDT $339,091 99,913 $3
PT $364,461 $25,370 99,845 68 $4 $374
M $395,788 99,905 $4 (Dominated)
0.075 RDT $338,076 99,881 $3
PT $365,064 $26,988 99,776 105 $4 $258
M $394,825 99,871 $4 (Dominated)
0.1 RDT $337,060 99,849 $3
PT $365,667 $28,607 99,708 142 $4 $202
M $393,861 99,838 $4 (Dominated)
0.125 RDT $336,045 99,818 $3
PT $366,269 $30,225 99,639 178 $4 $169
M $392,898 99,805 $4 (Dominated)
0.15 RDT $335,029 99,786 $3
PT $366,872 $31,843 99,571 215 $4 $148
M $391,934 99,772 $4 (Dominated)Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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ment of bacterial non-malarial febrile infection that could
be treated inappropriately with ACT using presumptive
treatment. Bacterial diseases are an important cause of
avoidable deaths in children in Africa [36-38].
At higher probability levels RDT also showed to be more
cost-effective compared to presumptive treatment and
microscopy. The reason for this could be explained by the
fact that higher NMFI implies low malaria prevalence,
which in turn provides strong reason for diagnostic test
before treatment. It also implies that if careful diagnosis is
not carried out, there could be higher probability of giving
malaria treatment to a patient with NMFI. This in turn has
high cost implication, especially when the cost of ACT is
considered. Again, at a low probability level of NMFI, pre-
sumptive treatment proves to be more cost-effective than
RDT, while microscopy is dominated at all levels of NMFI
cases. This implies that at low malaria prevalence, the
probability that non-malarial febrile infection is bacterial
should be important to decision makers.
Table 7: Report by RDT Sensitivity
P5 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.84 RDT $336,244 99,858 $3
PT $365,426 $29,182 99,735 123 $4 $237
M $394,247 99,851 $4 (Dominated)
0.87 RDT $336,957 99,861 $3
PT $365,426 $28,469 99,735 125 $4 $227
M $394,247 99,851 $4 (Dominated)
0.90 RDT $337,670 99,863 $3
PT $365,426 $27,756 99,735 127 $4 $218
M $394,247 99,851 $4 (Dominated)
0.94 RDT $338,383 99,865 $3
PT $365,426 $27,042 99,735 129 $4 $209
M $394,247 99,851 $4 (Dominated)
0.98 RDT $339,096 99,867 $3
PT $365,426 $26,329 99,735 131 $4 $200
M $394,247 99,851 $4 (Dominated)
Table 8: Report by Microscopy Sensitivity
P7 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.75 RDT $337,466 99,862 $3
PT $365,426 $27,959 99,735 127 $4 $221
M $392,820 99,847 $4 (Dominated)
0.82 RDT $337,466 99,862 $3
PT $365,426 $27,959 99,735 127 $4 $221
M $393,890 99,850 $4 (Dominated)
0.85 RDT $337,466 99,862 $3
PT $365,426 $27,959 99,735 127 $4 $221
M $394,960 99,854 $4 (Dominated)
0.90 RDT $337,466 99,862 $3
PT $365,426 $27,959 99,735 127 $4 $221
M $396,030 99,857 $4 (Dominated)
0.96 RDT $337,466 99,862 $3
PT $365,426 $27,959 99,735 127 $4 $221
M $397,100 99,860 $4 (Dominated)Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
Page 11 of 15
(page number not for citation purposes)
Cost-effectiveness of RDT and other diagnostic tools also
has much to do with adherence. The reason is because
when someone adheres to treatment there will be less
chances of going for second treatment option even though
the cost implication in the case of NMFI may not be so
much. NMFI also has cost-effectiveness impact on RDT
treatment based on the fact that presumptive treatment
may lead to antibiotics being given when a patient actu-
ally has malaria. Policy makers should, therefore, know
that cost-effectiveness of RDT can be greatly reduced if
there is poor ACT adherence level. In this study, patients
adhered to ACT treatment up to 80% level. Improvement
on this will further ensure a more effective result while
relapse will negatively affect the gains of RDT over pre-
sumptive treatment and microscopy. In Nigeria, ACT is
delivered free to children under five years in public health
facilities and this is likely to ensure that adherence level to
ACT is increased. However, it is worth noting that ACT
adherence can decrease as result of patients' and caretak-
ers forgetting to give the dose on certain days. They may
also have incomplete dose if they perceive that they are
cured after the initial few doses as have been noted in the
past, when chloroquine was being used as the first-line
anti-malarial drug [39]. Because of poverty, they may stop
taking the drugs after one or two doses, to save tablets for
later use by other members of the family.
Table 9: Report by Adherence to ACT Sensitivity
P11 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.4 RDT $359,976 99,836 $4
PT $390,437 $30,460 99,706 130 $4 $235
M $414,756 99,827 $4 (Dominated)
0.5275 RDT $352,801 99,844 $4
PT $382,464 $29,663 99,715 129 $4 $230
M $408,218 99,835 $4 (Dominated)
0.65 RDT $345,626 99,852 $3
PT $374,492 $28,866 99,725 128 $4 $226
M $401,681 99,843 $4 (Dominated)
0.80 RDT $338,451 99,861 $3
PT $366,520 $28,069 99,734 127 $4 $221
M $395,144 99,850 $4 (Dominated)
0.90 RDT $331,276 99,869 $3
PT $358,548 $27,272 99,743 126 $4 $216
M $388,607 99,858 $4 (Dominated)
Table 10: 50% rise in the cost of RDT
0.2 RDT $373,159 99,865 $4
M $388,888 99,826 $4 (Ext Dom)
PT $390,737 $17,578 99,662 202 $4 $87
0.3 RDT $376,314 99,874 $4
PT $378,081 $1,768 99,699 175 $4 $10
M $391,568 99,839 $4 (Dominated)
0.4 PT $365,426 99,735 $4
RDT $379,468 99,883 $4 (Dominated)
M $394,247 99,851 $4 (Dominated)
0.5 PT $352,770 99,772 $4
RDT $382,623 99,893 $4 (Dominated)
M $396,926 99,864 $4 (Dominated)
0.6 PT $340,114 99,808 $3
RDT $385,778 99,902 $4 (Dominated)
M $399,605 99,877 $4 (Dominated)Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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A doubling of the cost of RDT made it less preferable to
presumptive treatment. The implication of this is that pol-
icy makers should be more careful in choosing any policy
that will cause an increase in the cost of RDT as consumers
might become less willing to pay for the marginal increase
in the cost. Again, a rise in the cost of RDT that is not
checked by a corresponding decrease in the cost of ACT is
likely to result in presumptive treatment being preferred
over RDT and microscopy. In a low prevalence setting,
such a situation could further worsen the challenges asso-
ciated with inappropriate use of drugs including risk of
resistance, further disease progression and consequent
depletion of income. Thus, strategies must be in place to
prevent increase in the cost of RDT if it is to remain cost-
effective over other strategies especially at a declining
prevalence level.
If the price of ACT rises at the current malaria prevalence
level, treatment for malaria will be costly even for pre-
sumptive treatment with the cost of ACT significantly
driving the cost-effectiveness of RDT. Such a finding has
been noted elsewhere [28]. This calls for careful decision
Table 11: Rise in cost of ACT by 50% point
P1 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.2 RDT $361,076 99,865 $4
M $422,036 99,867 $4 (Dominated)
PT $512,996 99,977 $5 (Dominated)
0.3 RDT $375,054 99,874 $4
M $433,384 99,875 $4 (Dominated)
PT $500,683 99,974 $5 (Dominated)
0.4 RDT $389,031 99,883 $4
M $444,732 $55,701 99,882 1 $4 $51,008
PT $488,370 99,971 $5 (Dominated)
0.5 RDT $403,009 99,893 $4
M $456,080 $53,071 99,890 3 $5 $18,519
PT $476,057 99,968 $5 (Dominated)
0.6 RDT $416,986 99,902 $4
PT $463,744 99,965 $5 (Dominated)
M $467,428 $50,442 99,897 5 $5 $10,872
Table 12: Text report of reduced cost of Amoxicillin by 50% point
P1 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.2 RDT $301,037 99,953 $3
M $360,833 99,938 $4 (Ext Dom)
PT $390,737 $89,700 99,662 291 $4 $309
0.3 RDT $307,995 99,951 $3
M $366,187 99,937 $4 (Ext Dom)
PT $378,081 $70,086 99,699 253 $4 $278
0.4 RDT $314,952 99,950 $3
PT $365,426 $50,473 99,735 214 $4 $235
M $371,540 99,935 $4 (Dominated)
0.5 RDT $321,910 99,948 $3
PT $352,770 $30,860 99,772 176 $4 $175
M $376,894 99,934 $4 (Dominated)
0.6 RDT $328,867 99,946 $3
PT $340,114 £11,247 99,808 138 $3 $81
M $382,247 99,933 $4 (Dominated)Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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in fixing the price of ACT by any authority, as this could
overshoot the societal ability and willingness to pay, and
as well elude the cost containment of RDT. Considering
the fact that Nigeria has a significant rural population,
increasing the cost of ACT will make it further difficult for
people to seek treatment at the appropriate time. It could
also encourage presumptive treatment for two reasons: 1)
RDT would no longer be affordable, and 2) microscopy
with its high cost will not be affordable and available
especially in the remote villages.
As cost of ACT is currently high, unnecessary spending on
treatment that is not malaria can be avoided if RDT is used
to ascertain the true health condition. This will enable
health workers to treat malaria appropriately and at the
same time avoid extra burden of second-line treatment
cost.
On the other hand, a reduction in the cost of ACT which
made presumptive treatment more cost-effective than the
other options implies that consumers might end up pre-
ferring presumptive treatment strategy. Such a situation
was prevalent in the era of chloroquine use, a very cheap
anti-malarial drug. This means that with falling prices of
ACT, efforts must be made to keep consumers informed of
all the benefits of appropriate diagnosis of malaria,
including the fact that ACT could face the same fate as
chloroquine, if used inappropriately.
An incremental effect value that fluctuated drastically at
the 40% prevalence level, which is close to the prevalence
of 43.1% noted in this study, gives a clear picture of what
was obtained in Nigeria before the change in malaria
treatment regime. Before 2005, chloroquine was the first-
line drug for malaria treatment. Given the low cost of
chloroquine, people were given presumptive treatment on
the assumption that an average Nigerian has malaria par-
asites. The regime change made the cost of treatment to
rise, which simultaneously brought about the need to
ensure that one has malaria parasite before treatment so
as to avoid giving the costly ACT drug incorrectly. The
analysis however shows the need for a reduced cost of
ACT given that most people cannot afford the treatment
cost. It also shows that lower price of ACT will go a long
way to improving the treatment-seeking pattern of the
people, especially the poor and vulnerable.
Although studies have investigated the cost-effectiveness
of RDT in Africa [14,28-30], this study provides, the first
estimates of the cost-effectiveness of RDT in Nigeria. A
particular strength of this analysis is that costs are based
on relevant information from the study. However, the
results are also subject to a number of assumptions. The
sensitivity analysis showed, that the overall cost-effective-
ness of RDT is relatively robust to these assumptions. In
terms of extrapolation to parts of Nigeria, Enugu east LGA
is representative of areas of stable perennial malaria trans-
mission in Nigeria.
The primary limitation of the study is that effectiveness
was estimated from the results of the study where the
study team delivered ACT treatment free of charge. In
practice, availability of ACT may influence cost-effective-
ness because patients may not be able to purchase ACT as
a result of its high costs. However, this may not be neces-
Table 13: Text report of 50% rise in the cost of Amoxicillin
P1 Strategy Cost Incr Cost Eff Incr Eff C/E Incr C/E (ICER)
0.2 RDT $356,389 99,953 $4
PT $390,737 $34,348 99,662 291 $4 $118
M $415,001 99,938 $4 (Dominated)
0.3 RDT $357,353 99,951 $4
PT $378,081 $20,728 99,699 253 $4 $82
M $415,249 99,937 $4 (Dominated)
0.4 RDT $358,316 99,950 $4
PT $365,426 $7,109 99,735 214 $4 $33
M $415,496 99,935 $4 (Dominated)
0.5 PT $352,770 99,772 $4
RDT $359,280 99,948 $4 (Dominated)
M $415,744 99,934 $4 (Dominated)
0.6 PT $340,114 99,808 $3
RDT $360,243 99,946 $4 (Dominated)
M $415,991 99,933 $4 (Dominated)Malaria Journal 2009, 8:265 http://www.malariajournal.com/content/8/1/265
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sarily so for under-fives, that are officially given free ACT
in public facilities in Nigeria.
Secondly, all patients that were negative for malaria para-
sites were not given ACT. But in practice, health workers
may not adhere strictly to this as evidence has shown that
health workers are reluctant to refrain from treating for
malaria after a negative test [9,16,40,41], a practice that is
likely to reduce the cost-effectiveness of RDTs.
Thirdly, patients who were negative on microscopy or
RDT received amoxicillin systematically. Realizing that
not all these patients would require amoxicillin, they were
subsequently refereed for further investigations and man-
agement and may have gotten proper treatment for their
illnesses. This may have made RDTs more cost-effective
and thus biased the cost-effectiveness estimates. However,
the proportion of NMFI was too small as to have contrib-
uted to RDTs being more cost effective. Nevertheless, in
actual practice, health workers may prescribe antibiotics
to patients who are negative within the concept of inte-
grated management of childhood illnesses and when this
happens, it will even make RDTs more cost-effective.
Fourthly, clinical outcome rather than parasitological
clearance was used to assess effectiveness of treatment. It
is possible that parasitological clearance does not occur
following treatment despite the non-recurrence of fever
and this can influence the measure of effect since patients
recorded as having recovered could still have malaria par-
asites. However, it is noteworthy that since fever is the
major symptom that makes individuals seek health care,
those who do not have fever within 21 days of treatment
are unlikely to seek further care or incur additional
expenditure on treatment, thus limiting the potential bias
arising from use of clinical outcome for this analysis.
Finally, patients who reported prior anti-malarial drug
intake were not included in the study as this could cause
a possible bias considering the fact that having taken an
anti-malarial drug, their test results may have read nega-
tive implying that they don't have malaria, whereas they
may have had malaria prior to coming to the health cen-
tre. However, in this study, there were not a significant
number of them.
Conclusion
At the prevalence level of 43.1%, RDT was a cost effective
strategy for diagnosis of malaria in Nigeria. Policy makers
and healthcare providers can be confident that at the prev-
alence level of malaria in Nigeria, that it will be cost saving
to use RDTs rather than a syndromic approach and micro-
scopy. There is, therefore, increased opportunity for cost
savings if RDTs are introduced in health facilities espe-
cially in rural communities where microscopic examina-
tion for malaria diagnosis is not readily available. RDTs
decreased the number of false positive patients who
would have received unnecessary medication and thus
helped to prevent the erroneous treatment of fever caused
by other infections, and may reduce the drug resistance of
malaria. There are compelling reasons to justify the imple-
mentation of RDTs in Nigeria. Most of the health centres
that serve the Nigerian poor do not have microscopes or
trained technicians to examine blood films. Therefore, the
reliance on these rapid tests, which are reliable, cheap,
and simple enough to be used by non-laboratory staff, is
likely to greatly contribute to an effective control of malar-
iaThe wide application of RDT in Nigeria is also likely to
avoid the treatment of patients with bacterial disease with
the costly ACT and thus provide appropriate anti-bacterial
treatment for those with bacterial infection.
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